Reuters logo
BRIEF-Endocyte announces clinical updates for EC1456 and EC1169
June 2, 2017 / 12:11 PM / 6 months ago

BRIEF-Endocyte announces clinical updates for EC1456 and EC1169

June 2 (Reuters) - Endocyte Inc:

* Endocyte announces clinical updates for EC1456 and EC1169

* Endocyte Inc - continuing EC1169 program in taxane-exposed patients, but ending clinical development of EC1456 and of EC1169 in taxane-naïve patients

* Endocyte Inc - ‍restructuring to reduce workforce by approximately 40%; will maintain core competencies and preserve capital for highest priority programs​

* Endocyte Inc - refocusing efforts on chimeric antigen receptor t-cell (car t-cell) and dual-targeted dna crosslinker drug ec2629 programs

* Endocyte Inc - ‍endocyte will stop enrollment of taxane-naïve mcrpc patients in ec1169 trial​

* Endocyte Inc - plans to stop enrollment in ec1456 trial

* Endocyte Inc says anticipates one-time charges of approximately $2.4 million related to termination benefits and accelerated closure of ec1456 trial

* Endocyte inc says as a result of this restructuring, company is revising its guidance for 2017

* Endocyte inc - company plans to file its IND for ec2629 in mid-2017, which includes a potent DNA-targeted warhead with clinically proven activity

* Endocyte - will narrow ec1169 development program to focus only on cohort of taxane-exposed, metastatic castration-resistant prostate cancer patients

* Endocyte inc - anticipates one-time charges of approximately $2.4 million related to termination benefits and accelerated closure of ec1456 trial

* Endocyte inc says now expects its cash balance at end of 2017 to be approximately $105 million

* Endocyte inc - expects its cash balance at end of 2017 to be approximately $105 million, with a more substantial positive impact from restructuring beginning in 2018

* Endocyte- ‍interim assessment confirmed clinical activity of drug in taxane-exposed cohort with partial response in one patient, stable disease in other patients

* Endocyte Inc - top-line efficacy assessment of expansion phase of EC1169 phase 1 trial is expected before end of 2017

* Endocyte Inc says expects more substantial positive impact from restructuring beginning in 2018

* Endocyte Inc - plans to file its IND for ec2629 in mid-2017, which includes a potent DNA-targeted warhead with clinically proven activity

* Endocyte - advancing work with Seattle children’s research institute aimed at bringing its car t-cell bi-specific adaptor molecule to clinic in 2018​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below